| Bio Roundup: MESO’s Miss, Pfizer’s Cancer Bet, Vaccine Promise & More | Frank Vinluan | 10/02/20 | National |
| Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More | Frank Vinluan | 09/18/20 | National |
| Seattle Genetics Lands $1.72B From Merck in Pair of Cancer Drug Deals | Frank Vinluan | 09/14/20 | Seattle |
| Bio Roundup: COVID-19 Pact, Gavreto Approval, Generative Biology & More | Frank Vinluan | 09/11/20 | National |
| Moderna, Pfizer Protocols May Make COVID Vaccines Hard to Compare | Sarah Karlin-Smith | 08/07/20 | National |
| Bio Roundup: Cerevel’s Shell, Thrive’s Rise, Drug Price Drama & More | Frank Vinluan | 07/31/20 | National |
| Pfizer, BioNTech Choose Full Spike Protein for Pivotal Vaccine Test | Frank Vinluan | 07/28/20 | New York |
| AstraZeneca to Pay $1B to Team Up With Daiichi Sankyo Again in Cancer | Frank Vinluan | 07/27/20 | Europe |
| Bio Roundup: Jazz Drug OK’d, Gilead’s Bet, Moderna Patent Decision & More | Sarah de Crescenzo | 07/24/20 | National |
| Bio Roundup: Blackstone’s Billions, Biogen Finishes Filing, Novavax at “Warp Speed” & More | Sarah de Crescenzo | 07/10/20 | National |
| NFlection Looks to Erase NF1 Tumors With Drug That Only Goes Skin Deep | Frank Vinluan | 07/09/20 | Philadelphia |
| VelosBio Tacks on $137M to Advance Its ROR1-Targeting Cancer Antibody Drugs | Sarah de Crescenzo | 07/09/20 | San Diego |
| Novavax Gets $1.6B in Operation Warp Speed Funding for COVID-19 Vaccine | Sarah de Crescenzo | 07/07/20 | National |
| Moderna: Speed of COVID 19 Vaccine Hinges On Enrolling Right Patients | Sarah Karlin-Smith | 07/02/20 | National |
| Invitae Makes a Precision Oncology Push With $886M Deal for ArcherDx | Frank Vinluan | 06/22/20 | San Francisco |
| Engrail Therapeutics Launches With $32M to Develop New Neuro Drugs | Sarah de Crescenzo | 06/18/20 | San Diego |
| Viela Bio Gets FDA Green Light for Rare Autoimmune Disease Treatment | Sarah de Crescenzo | 06/12/20 | National |
| Biotech Roundup: BIO on Racism, AbbVie Antibodies, IPO Surge & More | Sarah de Crescenzo | 06/12/20 | National |
| Novo Nordisk Strikes a $725M Deal for AstraZeneca Spinout Corvidia | Frank Vinluan | 06/11/20 | Boston |
| Moderna Finalizes Plan, Dose for Phase 3 Test of mRNA COVID Vaccine | Frank Vinluan | 06/11/20 | Boston |
| Merck’s Keytruda Fails Pivotal Bladder Cancer Study, Sinks First-Line Hopes | Frank Vinluan | 06/10/20 | New York |
| Accent, AstraZeneca Ink Cancer Drug Deal to Block RNA-Modifying Proteins | Sarah de Crescenzo | 06/04/20 | Boston |
| Generation Bio Leads a Trio of Biotech Companies Aiming for the Nasdaq | Frank Vinluan | 05/22/20 | National |
| Bio Roundup: mRNA Vaccine Data, Rise of Rallybio, Roche’s Protein Play & More | Frank Vinluan | 05/22/20 | National |
| Bio Roundup: Acquisitive Alexion, CRISPR on COVID, C. diff Success & More | Frank Vinluan | 05/08/20 | National |
| AstraZeneca Diabetes Drug Gets FDA OK for Reducing Heart Health Risks | Sarah de Crescenzo | 05/06/20 | National |
| ADC Therapeutics Resubmits IPO to Fuel Cancer Drug Filing, Launch Plans | Frank Vinluan | 04/27/20 | New York |
| Bio Roundup: Alnylam’s Billions, COVID-19 Vaccines, Moma Debuts & More | Sarah de Crescenzo | 04/17/20 | National |
| RDMD Lands $14M to Expand Reach of Rare Disease Research Platform | Sarah de Crescenzo | 04/16/20 | San Francisco |
| AstraZeneca Wins First FDA Drug Nod for NF1, a Rare Genetic Disorder | Frank Vinluan | 04/10/20 | National |
